What is the 13F Pro Quality Score for CATX?

13F Pro ranks Perspective Therapeutics, Inc. (CATX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CATX's current score at https://13fpro.ai/company/CATX (free sign-up required for the full ranking).

Which hedge funds own the most CATX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CATX include BlackRock,, TCG Crossover Management,, Commodore Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CATX as soon as new 13F filings post.

Where does 13F Pro source CATX data?

All Perspective Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Perspective Therapeutics, Inc. files with the SEC under CIK 728387. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CATX in?

Perspective Therapeutics, Inc. (CATX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CATX research updated on 13F Pro?

CATX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Perspective Therapeutics, Inc.(CATX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 728387 CATX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

CATX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Perspective Therapeutics, Inc. (CATX), a Healthcare sector company. CATX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of CATX by reported 13-F value include BlackRock, TCG Crossover Management, Commodore Capital, based on the most recent SEC filings. CATX trades on the NYSE exchange and files with the SEC under CIK 728387. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CATX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Perspective Therapeutics, Inc. directly from SEC EDGAR.

D/E Ratio

FY 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Net Income

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Operating Income

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Total Assets

+26.2% YoY

$392.0MFY 2026

FY23 $120.1MFY24 $385.9MFY25 $310.7MFY26 $392.0M

Total Debt

-3.3% YoY

$1.6MFY 2026

FY23 $1.8MFY24 $1.7MFY25 $1.7MFY26 $1.6M

Op. Cash Flow

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Free Cash Flow

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	—	—	$10.8M +7.4%	$10.1M
Net Income	—	—	—	—	$-7.3M -114.7%	$-3.4M
Operating Income	—	—	—	—	$-7.4M -114.5%	$-3.4M
Total Assets	$392.0M +26.2%	$310.7M -19.5%	$385.9M +221.2%	$120.1M +86.4%	$64.4M -8.5%	$70.4M
Total Debt	$1.6M -3.3%	$1.7M -3.2%	$1.7M -3.8%	$1.8M	—	—
Operating Cash Flow	—	—	—	—	$-7.7M -171.8%	$-2.8M
Free Cash Flow	—	—	—	—	$-8.0M -147.9%	$-3.2M

AI Insight: CATX Financial Trends

Pre-revenue biotech burning cash at accelerating pace; equity volatility masks persistent operational deterioration.

• Operating losses widened from $19M (Q3 2024) to $28M (Q3 2025), with operating cash burn reaching $58M in Q3 2025.

• Equity base contracted from $328M (Q3 2024) to $207M (Q4 2025) before jumping to $347M by Q1 2026, suggesting dilutive financing.

• Total debt remained flat at $2M throughout period; balance sheet stress evident in equity erosion despite negligible leverage.

⚠ Operating cash burn accelerated to $58M in Q3 2025 — worst quarter on record — signaling runway pressure absent revenue.

⚠ Q1 2026 equity rebound to $347M suggests capital raise, but cash burn trajectory and net losses remain unsustainable without milestones.

AI Insight: CATX Ratio Trends

CATX remains deeply unprofitable with ROIC deteriorating to -45.7% in Q3 2025 before partial recovery to -32.4% in Q1 2026.

• ROIC collapsed from -22.6% in Q3 2024 to -45.7% in Q3 2025, representing a 23.1pp deterioration in operating returns.

• ROA worsened from -15.5% in Q3 2024 to -35.2% in Q3 2025, indicating asset utilization severely impaired.

• Leverage minimal and stable: D/E at 0.01 across all periods, reducing financial distress risk.

⚠ ROIC improved 13.3pp from Q3 2025 trough (-45.7%) to Q1 2026 (-32.4%), though still deeply negative.

⚠ Persistent negative returns across all profitability metrics suggest ongoing operating losses with no clear path to breakeven.

Get alerted when CATX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Perspective Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CATX

BlackRock, Inc.
$32.4M9,494,152 sh
TCG Crossover Management, LLC
$27.0M7,915,567 sh
Commodore Capital LP
$21.6M6,336,782 sh
Avidity Partners Management LP
$21.5M6,299,999 sh
STATE STREET CORP
$20.6M6,051,771 sh
MILLENNIUM MANAGEMENT LLC
$16.7M4,911,855 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.1M4,436,572 sh
Affinity Asset Advisors, LLC
$14.4M4,214,582 sh
CITADEL ADVISORS LLC
$13.0M3,805,739 sh
Spruce Street Capital LP
$12.6M3,693,931 sh

Fund	Value	Shares
BlackRock, Inc.	$32.4M	9,494,152
TCG Crossover Management, LLC	$27.0M	7,915,567
Commodore Capital LP	$21.6M	6,336,782
Avidity Partners Management LP	$21.5M	6,299,999
STATE STREET CORP	$20.6M	6,051,771
MILLENNIUM MANAGEMENT LLC	$16.7M	4,911,855
VANGUARD CAPITAL MANAGEMENT LLC	$15.1M	4,436,572
Affinity Asset Advisors, LLC	$14.4M	4,214,582
CITADEL ADVISORS LLC	$13.0M	3,805,739
Spruce Street Capital LP	$12.6M	3,693,931

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CATX on your watchlist

Track score changes the day Perspective Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CATX a good stock to buy?

13F Pro's AI-powered analysis of Perspective Therapeutics, Inc. (CATX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CATX are available on the CATX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CATX is classified as a small company.

Which hedge funds own CATX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CATX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Perspective Therapeutics, Inc.'s investment landscape.